公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2018 | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Kudo M.; Finn R.S.; Qin S.; Han K.-H.; Ikeda K.; Piscaglia F.; Baron A.; Park J.-W.; Han G.; Jassem J.; Blanc J.F.; Vogel A.; Komov D.; Evans T.R.J.; Lopez C.; Dutcus C.; Guo M.; Saito K.; Kraljevic S.; Tamai T.; Ren M.; ANN-LII CHENG | The Lancet | 3405 | 3008 | |
2010 | Liver cancer working group report | Kudo M.; Han K.H.; Kokudo N.; ANN-LII CHENG ; Choi B.I.; Furuse J.; Izumi N.; Park J.-W.; Poon R.T.; Sakamoto M. | Japanese Journal of Clinical Oncology | 54 | 53 | |
2018 | Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study | Kudo M.; ANN-LII CHENG ; Park J.-W.; Park J.H.; PO-CHIN LIANG ; Hidaka H.; Izumi N.; Heo J.; Lee Y.J.; Sheen I.-S.; Chiu C.-F.; Arioka H.; Morita S.; Arai Y. | The Lancet Gastroenterology and Hepatology | 126 | 114 | |
2014 | A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma | Lim H.Y.; Heo J.; Choi H.J.; Lin C.-Y.; Yoon J.-H.; CHIUN HSU ; Rau K.-M.; Poon R.T.P.; Yeo W.; Park J.-W.; Tay M.H.; Hsieh W.-S.; Kappeler C.; Rajagopalan P.; Krissel H.; Jeffers M.; Yen C.-J.; Tak W.Y. | Clinical Cancer Research | 95 | 85 | |
2021 | Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression | Ryoo B.-Y.; ANN-LII CHENG ; Ren Z.; Kim T.-Y.; Pan H.; Rau K.-M.; Choi H.J.; Park J.-W.; Kim J.H.; Yen C.J.; Lim H.Y.; Zhou D.; Straub J.; Scheele J.; Berghoff K.; Qin S. | British Journal of Cancer | 20 | 17 | |
2014 | Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel | ANN-LII CHENG ; Amarapurkar D.; Chao Y.; PEI-JER CHEN ; Geschwind J.-F.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; Park J.-W. | Liver International | 74 | 69 | |
2020 | Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial | Kelley R.K.; Ryoo B.-Y.; Merle P.; Park J.-W.; Bolondi L.; Chan S.L.; Lim H.Y.; Baron A.D.; Parnis F.; Knox J.; Cattan S.; Yau T.; Lougheed J.C.; Milwee S.; El-Khoueiry A.B.; ANN-LII CHENG ; Meyer T.; Abou-Alfa G.K. | ESMO open | 46 | 46 | |
2020 | Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma | Kelley R.K.; Meyer T.; Rimassa L.; Merle P.; Park J.-W.; Yau T.; Chan S.L.; Blanc J.-F.; Tam V.C.; Tran A.; Dadduzio V.; Markby D.W.; Kaldate R.; ANN-LII CHENG ; El-Khoueiry A.B.; Abou-Alfa G.K. | Clinical Cancer Research | 54 | 44 | |
2013 | Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial | ANN-LII CHENG ; Kang Y.-K.; Lin D.-Y.; Park J.-W.; Kudo M.; Qin S.; Chung H.-C.; Song X.; Xu J.; Poggi G.; Omata M.; Lowenthal S.P.; Lanzalone S.; Yang L.; Lechuga M.J.; Raymond E. | Journal of Clinical Oncology | 619 | 599 |